AN2 Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| AN2 Therapeutics, Inc. | ANTX - NASDAQ |
$14.00-$16.00 | $15.00 | $16.85 | 4.6 million | 3/25/2022 |
| Cowen, SVB Leerink, Evercore ISI | ||||||
Co-Manager(s): Oppenheimer | ||||||
| Health Care | ||||||
Filing(s): Filed 2022-03-04 Terms Added 2022-03-21 | ||||||
AN2 Therapeutics, Inc. Quote & Chart - Click for current quote - ANTX
IPO Boutique aggregates information on public companies and private companies, such as "ANTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About AN2 Therapeutics, Inc. (adapted from AN2 Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ANTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.